Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
GIC shares dip 4% as Rs 3,088 crore OFS opens for retail investors. Should you participate?
General Insurance Corporation of India shares dropped 4% as the government's OFS opens for retail investors today at a discount. Meanwhile, Zydus Lifesciences successfully completed its cash tender offer for Assertio Holdings Inc., making it a wholly-owned subsidiary. This acquisition aims to boost Zydus's pipeline of innovative drugs.
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.
Zydus Lifesciences share buyback to open on 4 June: Should you participate or not?
Ahead of the buyback opening, Zydus Life stock was trading 2.5% lower at ₹1,063 apiece on Tuesday, 2 June. Here are the buyback details, along with experts' opinions on whether retail investors should participate.
Stocks to Watch for May 29: Zydus Life, Patanjali, RIL, Swiggy, Godfrey Phillips and more
From Zydus Lifesciences raising its buyback price and Reliance Industries announcing its AGM and dividend record date, to PhysicsWallah sharply narrowing Q4 losses on strong revenue growth, here are the stocks to watch ahead of Friday’s trading session.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Zydus Lifesciences to pursue acquisitions in specialty, rare diseases
Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology business in the US. The company reported robust financial growth for the fourth quarter of 2025-26. Zydus also announced a share buyback and a dividend. Future growth is expected from its specialty portfolio.
Trade Spotlight: How should you trade Zydus Lifesciences, Laurus Labs, Global Health, Ather Energy, Info Edge India, and others on June 24?
The market is expected to consolidate with range-bound trading as long as it trades below the previous week's high. Below are some short-term trading ideas to consider.
Zydus Lifesciences gains traction amid US oncology drug shortages
From complex generics to speciality medicines, the drug maker is building a differentiated growth engine